Target intelligence / Profile preview

Secretogranin V (SCG5)

Target
SCG5
Molecular classification
Other (Granins family; secreted chaperone protein)
01

Overview

Secretogranin V (SCG5), also known as neuroendocrine protein 7B2, is a secreted chaperone protein highly expressed in neuroendocrine tissues. Its main biological function is to prevent the aggregation of secreted proteins, notably including those related to neurodegenerative and metabolic disorders. SCG5 acts as a chaperone for prohormone convertase PC2, facilitating its transport and activation in the secretory pathway, and it also participates in pituitary hormone regulation. Importantly, SCG5/7B2 demonstrates anti-aggregation properties against amyloid-β and α-synuclein, thus providing cellular protection against neurotoxicity. In certain cancers, such as medulloblastoma, epigenetic silencing of the SCG5 gene is linked to enhanced tumor cell proliferation, suggesting a tumor suppressor role. SCG5 belongs to the granin family and is considered multifunctional, critical for maintaining neural and endocrine integrity[1][2][3].

Other names
Neuroendocrine protein 7B2SGNE17B2SgVPituitary polypeptideSecretogranin-5Secretory granule endocrine protein Iprohormone convertase chaperoneP7B2
02

Biological functions

Chaperone activity for secreted proteinsPrevents aggregation of proteins associated with neurodegenerative and metabolic diseaseTrafficking and activation of prohormone convertase PC2Regulates pituitary hormone secretionTumor suppressor activity in neuroendocrine tissues
03

Disease associations

Neurodegenerative disease (e.g., prevention of amyloid-β and α-synuclein aggregation)Medulloblastoma (epigenetic silencing leads to tumorigenesis)Polyposis Syndrome, Hereditary Mixed, 1Ataxia-Telangiectasia
04

Safety considerations

No specific therapeutic safety concerns identified; it is important for protein aggregation prevention, so dysfunction may contribute to disease
05

Biomarkers

Potential biomarker for neurodegenerative disease riskPotential biomarker for tumor suppression in neuroendocrine tissues

Beyond the preview

Go deeper on Secretogranin V (SCG5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Secretogranin V (SCG5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call